Human Health
From veterinary validation
to human trials
INITIAL INDICATION
Why melanoma first
Melanoma incidence keeps climbing, the diagnosed population is large, and the market is on track to roughly double — a clear first indication for intratumoral delivery.
Strong Phase I results at Moffitt Cancer Center support the intratumoral electroporation approach in human melanoma.
Source: NCI SEER prevalence estimate.
1.4%
Annual incidence growth
1.17M
Prevalent US patients
~2x
Projected market growth within a decade
Regulatory pathway
LifePulse™ filed a successful pre-submission with the FDA and has a predicate device for ablation the FDA has allowed before. We anticipate obtaining our 510(k) clearance, filing an IDE for drug delivery and a clinical trial in metastatic melanoma, and also filing for breakthrough status.
